Literature DB >> 33346795

Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic.

Thuy D Nguyen1, Sumedha Gupta2, Engy Ziedan3, Kosali I Simon4, G Caleb Alexander5, Brendan Saloner6, Bradley D Stein7.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33346795      PMCID: PMC7754073          DOI: 10.1001/jamainternmed.2020.7497

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  18 in total

1.  The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.

Authors:  Hannah K Knudsen; Jeanie Hartman; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2022-01-29       Impact factor: 4.492

2.  Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021.

Authors:  Kao-Ping Chua; Chin Hwa Y Dahlem; Thuy D Nguyen; Chad M Brummett; Rena M Conti; Amy S Bohnert; Aaron D Dora-Laskey; Keith E Kocher
Journal:  Ann Emerg Med       Date:  2021-11-19       Impact factor: 5.721

3.  Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.

Authors:  Lewei Allison Lin; Lan Zhang; Hyungjin Myra Kim; Madeline C Frost
Journal:  Am J Psychiatry       Date:  2022-07-28       Impact factor: 19.242

Review 4.  Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond.

Authors:  Seema Choksy Pessar; Anne Boustead; Yimin Ge; Rosanna Smart; Rosalie Liccardo Pacula
Journal:  JAMA Health Forum       Date:  2021-11-19

5.  Opioid-related Emergency Department Visits During COVID-19 in a Large Health System.

Authors:  Gavin T Hall; Daniel S Cruz; Patrick M Lank; Danielle M McCarthy; Howard S Kim
Journal:  J Addict Med       Date:  2021 Jul-Aug 01       Impact factor: 4.647

Review 6.  Mechanical ventilation parameters in critically ill COVID-19 patients: a scoping review.

Authors:  Giacomo Grasselli; Emanuele Cattaneo; Gaetano Florio; Mariachiara Ippolito; Alberto Zanella; Andrea Cortegiani; Jianbo Huang; Antonio Pesenti; Sharon Einav
Journal:  Crit Care       Date:  2021-03-20       Impact factor: 9.097

7.  The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill.

Authors:  Thuy Nguyen; Ulrike Muench; Barbara Andraka-Christou; Kosali Simon; W David Bradford; Joanne Spetz
Journal:  Med Care Res Rev       Date:  2021-04-01       Impact factor: 3.929

Review 8.  Trends in visits to substance use disorder treatment facilities in 2020.

Authors:  Jonathan Cantor; David Kravitz; Mark Sorbero; Barbara Andraka-Christou; Christopher Whaley; Kathryn Bouskill; Bradley D Stein
Journal:  J Subst Abuse Treat       Date:  2021-05-11

9.  Prescription Drug Dispensing to US Children During the COVID-19 Pandemic.

Authors:  Kao-Ping Chua; Anna Volerman; Rena M Conti
Journal:  Pediatrics       Date:  2021-07-20       Impact factor: 9.703

10.  Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database.

Authors:  Brendan Saloner; Penn Whitley; Leah LaRue; Eric Dawson; Angela Huskey
Journal:  JAMA Netw Open       Date:  2021-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.